Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Biotinylated Red Blood Cells

Phase 1Small molecule

JJohn A Widness

1

Indications

2

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

SurvivalNot yet recruiting

SurvivalPhase 1

Not yet recruiting

Timeline

Expected Milestones

Q4 2027

Phase 1Not yet recruiting

Survival

NCT07446647

Clinical

Trials by Indication[1]

Survival1 trial

Comparative Analysis of Biotinylated, Irradiated and 51-Chromium Radiolabeled Red Blood Cells for Analysis of Recovery and Survival After Autologous Transfusion

Not yet recruiting·JJose Cancelas·Phase 1·NCT07446647·20 enrolled

Neonatal1 trial

Optimized EPO Treatment of Neonatal Anemia

Completed·JJohn A Widness·Phase 2·NCT02075970·33 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Biotinylated Red Blood Cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Biotinylated Red Blood Cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Biotinylated Red Blood Cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — John A Widness company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: JJohn A Widness

Related News